Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Valeant Adds Eyetech’s Macugen To Ophthalmic Portfolio

This article was originally published in The Pink Sheet Daily

Executive Summary

The acquisitive Canadian specialty pharma’s latest deal is a relatively small one, giving it a wet AMD treatment that lags behind Lucentis and other newcomers.

You may also be interested in...



On The Road And Through The Window: Inside Three Biotech IPOs

Ophthotech, OncoMed, and bluebird bio are three of the dozens of biotechs that have made public debuts this year. Here’s how they did it, and the decisions they made to take advantage of being in the right place at the right time.

NICE OK For Bayer’s Eylea In AMD May Spell U.K. Trouble For Lucentis

NICE has given the thumbs-up to Bayer’s Eylea in wet AMD, but its impressive cost-effectiveness could spell trouble for Novartis’ Lucentis in the long run.

Eye On The Prize: For $8.7 Billion, Valeant Will Acquire Bausch & Lomb

As with its Medicis buyout in 2012, Valeant is acquiring another company to serve essentially as a therapeutic division within the specialty pharma the Canadian firm is cobbling together from relentless M&A activity. Buying B&L will increase Valeant’s eye care holdings substantially.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073756

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel